These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23770674)

  • 21. Early life experiences and adult attachment in obsessive-compulsive disorder. Part 2: Therapeutic effectiveness of combined cognitive behavioural therapy and pharmacotherapy in treatment-resistant inpatients.
    Hodny F; Ociskova M; Prasko J; Vanek J; Visnovsky J; Sollar T; Slepecky M; Nesnídal V; Kolek A
    Neuro Endocrinol Lett; 2022 Dec; 43(6):345-358. PubMed ID: 36716392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting the therapeutic response to cognitive behavioural therapy in patients with pharmacoresistant obsessive-compulsive disorder.
    Prasko J; Raszka M; Adamcova K; Grambal A; Koprivova J; Kudrnovská H; Latalova K; Vyskocilová J
    Neuro Endocrinol Lett; 2009; 30(5):615-23. PubMed ID: 20035255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early life experiences and adult attachment in obsessive-compulsive disorder. Part 1: Relationships between demographic, clinical, and psychological factors in pharmacoresistant OCD.
    Hodny F; Ociskova M; Prasko J; Houdkova M; Vanek J; Sollar T; Visnovsky J; Slepecky M; Nesnídal V; Latalova K; Kolek A; Bocek J
    Neuro Endocrinol Lett; 2022 Dec; 43(6):333-344. PubMed ID: 36716391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An exploratory dimensional approach to premenstrual manifestation of obsessive-compulsive disorder symptoms: a multicentre study.
    Moreira L; Bins H; Toressan R; Ferro C; Harttmann T; Petribú K; Juruena MF; do Rosário MC; Ferrão YA
    J Psychosom Res; 2013 Apr; 74(4):313-9. PubMed ID: 23497833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy.
    Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W
    J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.
    Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M
    J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mindfulness-based cognitive therapy in obsessive-compulsive disorder: protocol of a randomized controlled trial.
    Külz AK; Landmann S; Cludius B; Hottenrott B; Rose N; Heidenreich T; Hertenstein E; Voderholzer U; Moritz S
    BMC Psychiatry; 2014 Nov; 14():314. PubMed ID: 25403813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impulse control disorders in patients with obsessive-compulsive disorder.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychiatry Clin Neurosci; 2005 Feb; 59(1):30-7. PubMed ID: 15679537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term Outcomes of Intensive Inpatient Care for Severe, Resistant Obsessive-Compulsive Disorder: Résultats à long terme de soins intensifs à des patients hospitalisés pour un trouble obsessionnel-compulsif grave et résistant.
    Balachander S; Bajaj A; Hazari N; Kumar A; Anand N; Manjula M; Sudhir PM; Cherian AV; Narayanaswamy JC; Jaisoorya TS; Math SB; Kandavel T; Arumugham SS; Janardhan Reddy YC
    Can J Psychiatry; 2020 Nov; 65(11):779-789. PubMed ID: 32452212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are trauma and dissociation related to treatment resistance in patients with obsessive-compulsive disorder?
    Semiz UB; Inanc L; Bezgin CH
    Soc Psychiatry Psychiatr Epidemiol; 2014 Aug; 49(8):1287-96. PubMed ID: 24213522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of obsessive-compulsive disorder complicated by comorbid eating disorders.
    Simpson HB; Wetterneck CT; Cahill SP; Steinglass JE; Franklin ME; Leonard RC; Weltzin TE; Riemann BC
    Cogn Behav Ther; 2013; 42(1):64-76. PubMed ID: 23316878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paroxetine treatment of compulsive hoarding.
    Saxena S; Brody AL; Maidment KM; Baxter LR
    J Psychiatr Res; 2007 Sep; 41(6):481-7. PubMed ID: 16790250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.